Medina DJ, Tung PP, Strair RK; Conference on Retroviruses and Opportunistic Infections.

Program Abstr 3rd Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 3rd 1996 Wash D C. 1996 Jan 28-Feb 1; 3rd: 117.

Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ.

Recent clinical studies have demonstrated that early HIV-1 replication after initiation of Zidovudine (AZT) is generally a consequence of the replication of AZT-sensitive virus (Loveday et aI., 1995. Lancet 345:820-825). Analysis of a cell line refractory to the antiviral effects of AZT indicates decreased accumulation of AZTTP, increased phosphorylation of thymidine to TTP and increased levels of thymidine kinase activity compared to a control cell line (Medina et al. 1995. J. Virol. 69:1606-1611). Metabolic characterization of these cells has led to the development of a novel combination therapy designed to potentate the antiviral efficacy of AZT. This report describes the antiviral effects of the combination of floxuridine and AZT. This combination suppresses early viral breakthrough, lowers the IC50 of AZT, and has particular antiviral efficacy in the subset of cells that are infected with AZT-sensitive virus in the presence of AZT, The antiviral efficacy of this combination in PBMC suggests potential clinical utility.

Publication Types:

• Meeting Abstracts

Keywords:

• 3'-azido-3'-deoxythymidine 5'-triphosphate
• Antiviral Agents
• Cell Line
• Floxuridine
• HIV-1
• Thymidine
• Thymidine Kinase
• Thymine Nucleotides
• Zidovudine
• reverse transcriptase, Human immunodeficiency virus 1

Other ID:

• 96920344

UI: 102216395

From Meeting Abstracts